Pere Ginès
Ginès, Pere
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Ginès i Gibert, Pere
VIAF ID: 86958196 (Personal)
Permalink: http://viaf.org/viaf/86958196
Preferred Forms
-
100 1 _
‡a
Ginès, Pere
-
100 1 _ ‡a Ginès, Pere
-
100 1 _ ‡a Ginès, Pere
-
100 1 _
‡a
Ginès, Pere
-
100 1 _
‡a
Ginès, Pere
-
100 1 _ ‡a Ginès i Gibert, Pere
-
100 1 _
‡a
Ginès i Gibert, Pere
-
100 1 _ ‡a Ginès, Pere
-
100 1 _
‡a
Ginès, Pere
-
100 1 _ ‡a Ginès, Pere
-
100 0 _
‡a
Pere Ginès
4xx's: Alternate Name Forms (7)
Works
| Title | Sources |
|---|---|
| Ascites and renal dysfunction in liver disease : pathogenesis, diagnosis, and treatment |
|
| Autotest: gastroenterología y hepatología |
|
| Avaluació d'un programa d'infermeria d'atenció immediata a persones amb problemes de salut aguts lleus |
|
| Chronic liver failure : mechanisms and management |
|
| Contribució a l'estudi de la hiponatrèmia a la cirrosi hepàtica : descripció d'una nova causa i implicacions sobre la qualitat de vida dels pacients |
|
| Contribución al estudio de la insuficiencia renal asociada a infecciones en la cirrosis : utilidad de la neutrophil gelatinase-associated lipocalin |
|
| Efecte de l'administració de seroalbúmina en el deteriorament de la funció renal i la mortalitat dels pacients amb peritonitis bacteriana espontània |
|
| Estudio de los microRNAs en la fisiopatología de la hepatitis alcohólica |
|
| Expresión Génica Hepática en pacientes con hepatopatías crónicas : identificacación de dianas terapéuticas y evaluación de un tratamiento antifibrogénico |
|
| Hepatitis alcohólica[Recurs electrònic] : estratificación pronóstica e identificación de mecanismos patogénicos |
|
| Insuficiencia renal en la cirrosis evaluación de nuevas clasificaciones pronósticas y tratamiento del síndrome hepato-renal tipo 1 asociado a sepsis |
|
| Insuficiència renal funcional en la cirrosi hepàtica amb ascites. Factors predictius, diagnòstic i assaig de noves mesures terapèutiques |
|
| Investigació de les bases cel·lulars i moleculars de la fibrosi hepàtica : paper dels sistemes vasoactius |
|
| Investigación de los efectos de las sustancias vasodilatadoras en las células estrelladas hepáticas |
|
| Investigación del papel de la hiponatremia como factor de riesgo de encefalopatía hepática en la cirrosis |
|
| Natural history of hepatocellular carcinoma in Spain |
|
| [Neutropenia caused by penicillin] |
|
| A new scoring system for prognostic stratification of patients with alcoholic hepatitis. |
|
| [New therapeutic strategies in liver fibrosis: pathogenic basis] |
|
| Official congress report Autoimmune diseases of the liver Falk Symposium 197, Lisbon, May 8-9, 2015 |
|
| [Pancreatic ascites. Study of 3 cases and review of the literature] |
|
| La Paracentesi en el tractament dels malalts cirròtics amb ascites |
|
| Pathophysiology of renal dysfunction in cirrhosis. |
|
| A patient with cirrhosis and increasing creatinine level: what is it and what to do? |
|
| Peripheral arterial vasodilatation: determinant of functional spectrum of cirrhosis. |
|
| [Physiopathology of ascites in cirrhosis. A multidisciplinary problem] |
|
| Predicting mortality in cirrhosis--serum sodium helps |
|
| Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study |
|
| Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA |
|
| Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study |
|
| Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis |
|
| Prognostic value and treatment of hyponatremia in patients with advanced cirrhosis and acute on chronic liver failure |
|
| Refractory ascites: definition and mechanism |
|
| Renal effects of amino acid administration in cirrhosis |
|
| Renal failure after upper gastrointestinal bleeding in cirrhosis: Incidence, clinical course, predictive factors, and short-term prognosis |
|
| Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis. |
|
| Reply to: "Acute-on-chronic liver failure - its definition remains unclear". |
|
| Reply to: "To close the stable door before the horse has bolted". |
|
| Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. |
|
| Review article: albumin for circulatory support in patients with cirrhosis. |
|
| Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development. |
|
| Síndrome hepatorenal: nuevos aspectos fisiopatológicos y terapéuticos |
|
| Stenosis of the suprahepatic inferior vena cava as a complication of transjugular intrahepatic portosystemic shunt in Budd-Chiari patients. |
|
| Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. |
|
| Therapy in liver diseases |
|
| Therapy with vasoconstrictor drugs in cirrhosis: The time has arrived |
|
| [Thrombocytopenic purpura and acute nephropathy associated with circulating immune complexes in hepatitis A virus infection] |
|
| TIPS and refractory ascites. Lessons from the recent history of ascites therapy |
|
| Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. |
|
| Total paracentesis with dextran 40 vs diuretics in the treatment of ascites in cirrhosis: a randomized controlled study |
|
| Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. |
|
| Transient increase in urine protein excretion during treatment with terlipressin and albumin for type-1 hepatorenal syndrome |
|
| Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems |
|
| Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. |
|
| Trastorn circulatori postparacentesi. Incidència, implicacions pronòstiques i prevenció amb expansors plasmàtics |
|
| Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival. |
|
| Tyrosine kinase growth factor receptors but not seven-membrane-spanning receptors or phorbol esters activate mitogen-activated protein kinase in rat hepatocytes. |
|
| Upregulation of endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats |
|
| Urinary excretion of 6-keto-prostaglandin F1α, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites |
|
| Urinary excretion of endogenous digitalis-like natriuretic substances in healthy subjects. Effect of sodium load. |
|
| Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. |
|
| Utilidad del MELD y el sodio pretrasplante en el pronóstico del trasplante hepático a corto plazo |
|
| Valoración de la Función Ventricular Izquierda en la Cirrosis Hepática: Relación con la Hemodinámica Sistémica y la Disfunción Renal |
|
| Vaptans: a promising therapy in the management of advanced cirrhosis. |
|
| [Vasoconstrictors in the treatment of hepatorenal syndrome] |
|
| Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats. |
|
| Vasopressin in pathophysiological states. |
|
| What's new in the treatment of ascites and spontaneous bacterial peritonitis. |
|
